- How the 26 Content Areas Fit Together
- Phase I Foundations: Domains 1-9
- Phase I Organ Systems and Drug Classes: Domains 10-22
- Phase II Subject Categories: Domains 23-26
- Exam Format, Fees and Logistics
- Eligibility, Papers and the Five-Year Window
- Sequencing the Domains Across Your Preparation
- Where Diplomates Work
- Frequently Asked Questions
- Domains 1-22 come from the dated December 2021 Phase I preparation blueprint; Domains 23-26 are the four current Phase II subject categories.
- The "26" is a count of supplied headings, not an official combined exam-domain total, and no weights are published here.
- Phase I is 200 multiple-choice questions in two 100-question sessions; Phase II is ten question groups worth 200 points.
- Published 2026 fees: USD 75 Phase I application, USD 200 Phase I exam, USD 250 credentials review, USD 300 Phase II exam.
How the 26 Content Areas Fit Together
The American College of Veterinary Clinical Pharmacology (ACVCP) awards the DACVCP credential through a two-phase examination. Candidates must pass both Phase I and Phase II. Understanding where each of the 26 content areas comes from is the first step in studying them correctly, because they do not all share the same provenance.
Domains 1 through 22 are the preparation headings from the ACVCP's Suggested Blueprint for Phase I, last revised December 2021. Domains 23 through 26 are the four examination subject categories listed on the current Phase II Examination page: Therapeutics; Pharmacokinetics and Therapeutic Drug Monitoring; Experimental Design, Statistics and Analytical Methods; and Regulatory Pharmacology.
Treat this guide as a map of the territory, not a scoring formula. For related planning questions, see the DACVCP Study Guide and the overview of what DACVCP certification is.
Phase I Foundations: Domains 1-9
The first nine headings are the principles that every later system-based question rests on. A candidate who is fluent here can reason through unfamiliar drugs; a candidate who has only memorized drug lists cannot.
Domain 1: Physiochemical characteristics of active pharmaceutical ingredients
Note the spelling: the source heading uses "Physiochemical." This domain covers the molecular properties that drive everything downstream.
- Ionization, pKa and how pH shifts the ionized fraction across membranes
- Lipophilicity, solubility and their effect on absorption and distribution
- Stability and formulation implications of a compound's chemistry
Domain 2: Pharmacodynamics
What the drug does to the body: receptors, signal transduction and dose-response behavior.
- Agonism, partial agonism, antagonism and inverse agonism
- Potency versus efficacy, and how to read a dose-response curve
- Tolerance, desensitization and receptor regulation
Domain 3: Drug movement
The mechanisms by which molecules cross biological barriers.
- Passive diffusion, facilitated transport and active transport
- Efflux and uptake transporters, including their role at barriers such as the blood-brain barrier
- Species and breed differences in transporter function
Domain 4: Pharmacokinetics
The quantitative description of absorption, distribution, metabolism and elimination.
- Compartmental and noncompartmental concepts
- Clearance, volume of distribution, half-life and bioavailability and how they relate
- Accumulation, steady state and loading versus maintenance dosing
Domain 5: Factors impacting drug movement and/or drug response
Why the same dose behaves differently across patients.
- Age, disease, species and breed effects, including pharmacogenetic variation
- Drug-drug interactions at metabolic and transporter levels
- Protein binding and its clinical relevance
Domain 6: Routes of administration
How the route shapes onset, bioavailability and risk.
- Oral, parenteral, transdermal, inhalational, ocular and other routes
- First-pass effects and the species-specific anatomy that modifies them
Domain 7: Dosing forms (and relevant drug delivery devices)
The product, not just the molecule.
- Immediate versus extended-release behavior and what changes when forms are altered
- Delivery devices and their effect on dose delivered to the patient
Domain 8: Adverse events
Recognizing, classifying and attributing harm.
- Dose-dependent versus idiosyncratic reactions
- Organ-specific toxicity patterns and the drugs that cause them
- Causality assessment and reporting concepts
Domain 9: Causes for therapeutic failure
A diagnostic-style domain that rewards structured reasoning.
- Pharmacokinetic causes: poor absorption, rapid clearance, wrong dose
- Pharmacodynamic causes: resistance, receptor changes, wrong target
- Practical causes: formulation, compliance and misdiagnosis
Phase I Organ Systems and Drug Classes: Domains 10-22
The next thirteen headings shift from principles to applied pharmacology by body system or drug class. Expect questions that ask you to integrate Domains 1-9 reasoning with a specific therapeutic area.
| Domain | Heading | Typical integration with core principles |
|---|---|---|
| 10 | Nervous System | Receptor pharmacology, CNS penetration and transporter effects |
| 11 | Renal | Diuretic mechanisms, nephrotoxicity, renal dose adjustment |
| 12 | Cardiovascular | Inotropes, antiarrhythmics, vasoactive agents, narrow therapeutic windows |
| 13 | Gastrointestinal | Acid suppression, motility, antiemetics, route and formulation issues |
| 14 | Reproduction | Hormonal agents, species-specific use, safety concerns |
| 15 | Endocrine | Feedback regulation, replacement and suppression therapy |
| 16 | General and special senses | Ocular and otic delivery, local versus systemic exposure |
| 17 | Control of inflammation/immunomodulation | Anti-inflammatory and immunosuppressive mechanisms and toxicities |
| 18 | Anticancer drugs | Cytotoxic mechanisms, dosing strategies, handling and toxicity |
| 19 | Fluid therapy | Crystalloids, colloids, electrolyte and acid-base effects |
| 20 | Anti-infectives | PK/PD targets, resistance and spectrum considerations |
| 21 | Botanical/Herbals | Active constituents, interaction potential, evidence limitations |
| 22 | Disinfectants/antiseptics | Mechanism, spectrum, toxicity and appropriate use |
A useful drill for this block is to take any drug and walk it through the foundations: its chemistry (Domain 1), target (2), movement (3), kinetics (4), modifiers (5), route and form (6, 7), adverse events (8) and failure modes (9). If you can narrate that chain for a representative drug in each system, the system-based questions become manageable.
Phase II Subject Categories: Domains 23-26
Phase II is where the credential diverges sharply from a drug-knowledge exam. The four subject categories on the current Phase II Examination page emphasize applied reasoning, data interpretation and regulatory fluency. Current category percentages are not published on that page, and the historical question allocations in the December 2021 Phase II blueprint should not be treated as current weights.
Domain 23: Therapeutics
Case-oriented clinical decision making.
- Selecting, dosing and monitoring drugs for a presented patient problem
- Justifying choices from mechanism, kinetics and evidence
- Anticipating interactions, adverse events and reasons for failure
Domain 24: Pharmacokinetics and Therapeutic Drug Monitoring
Quantitative work with real concentration data.
- Calculating parameters and adjusting regimens from measured concentrations
- Choosing sampling times and interpreting peaks, troughs and exposure measures
- Knowing when monitoring adds value and when it does not
Domain 25: Experimental Design, Statistics and Analytical Methods
The research-literacy domain, which aligns with the paper requirements for Phase II eligibility.
- Study design choices, bias control and sample size reasoning
- Appropriate statistical tests and interpretation of results
- Bioanalytical method concepts, including validation and assay performance
Domain 26: Regulatory Pharmacology
How veterinary drugs are evaluated, approved and used.
- Approval pathways and the evidence expected to support them
- Labeled versus extralabel use and the responsibilities that come with it
- Safety, quality and post-approval concepts
Because Phase II mixes written responses with multiple choice, fill-in-the-blank and extended matching, practice writing your reasoning, not just recognizing it. For more on how demanding this combination is, see how hard the DACVCP exam is.
Exam Format, Fees and Logistics
The structural differences between the two phases shape how you should prepare for the domains above.
| Element | Phase I | Phase II |
|---|---|---|
| Structure | 200 multiple-choice questions in two 100-question sessions | Ten question groups worth 200 points across two 100-point sessions |
| Question types | Multiple choice | Written responses, multiple choice, fill-in-the-blank, extended matching |
| Ordinary schedule | 08:00-12:00 and 14:00-18:00 local time; eight active hours | Eight active hours ordinarily |
| 2026 administration | May 19, remote via ExamSoft | June 30, remote via ExamSoft |
| 2026 exam fee | USD 200 | USD 300 |
| Other published fee | USD 75 application | USD 250 credentials review |
The Phase II point total of 200 is not a question count, so do not plan on 200 items. The 2026 dates above have passed, and a 2027 schedule was not verified; check DACVCP exam dates and the ACVCP Candidate Information page for the next cycle.
The remote testing setup
Candidates supply a compatible Windows or Mac laptop with Examplify installed and administrator privileges. Encrypted exam files are downloaded and unlocked with a proctor password, and examination mode blocks internet access, files and other applications. Advance practice examinations are offered so you can rehearse the software and become familiar with question structure. Use them; a software surprise on exam day is an avoidable cost.
Fee mechanics worth understanding
Retakes require the respective examination fee again. The general fee page permits refunds only for extenuating circumstances accepted by the Board, while the phase pages describe examination fees as nonrefundable, so budget as though they are final. The Becoming a Resident page also mentions a USD 75 first-year candidate registration fee; the public pages do not establish whether that is the same as or additional to the Phase I application charge, so confirm with the ACVCP before budgeting. For the full picture, see the DACVCP certification cost breakdown.
Eligibility, Papers and the Five-Year Window
The domains are only half the challenge. The credential is gated by training and publication requirements that influence when you can sit for each phase.
Phase I eligibility
Applicants must be legally qualified to practice veterinary medicine and enrolled in, or have completed, approved ACVCP residency training. The application requires two references. Approved institutional and alternate training routes are described in the ACVCP's Becoming a Resident and Residency Training Programs pages. The broad residency learning outcomes published there do not add to the domain count discussed in this article. See also DACVCP requirements and DACVCP training.
Phase II credentials
- Completed approved training and a Phase I pass
- Approved credentials, with course documentation and transcripts
- Two peer-reviewed papers accepted or published by February 1 of the examination year
- At least one paper must be original veterinary clinical pharmacology research; the other may be original research or an eligible evidence-based systematic review or meta-analysis
- First authorship on at least one paper
- Neither paper may have been used for another specialty board, and publication must not predate the start of training by more than two years
Applications are ordinarily due October 1 before the examination year, with intent to sit due February 1. The currently dated checklist covers October 1, 2025 and February 1, 2026. Your publication timeline directly constrains your Phase II timeline, which is why Domain 25 (experimental design and statistics) deserves early attention: the same skills you use to produce your papers are tested.
The five-year eligibility window
Both phases must be passed within a five-year period beginning with the first eligible examination year after Phase I approval. The issuer's example: approval in December 2025 permits the 2026-2030 examinations. This is an examination eligibility window, not a credential renewal interval. Historical bylaws (approved June 2018) describe maintenance-record review, but their current applicability was not verified, and no current renewal hours, fees or interval should be inferred. The Maintenance of Certification committee administers recertification; confirm current rules with the ACVCP directly.
Sequencing the Domains Across Your Preparation
Because the content areas build on one another, order matters more than raw hours. The sketch below ties the sequence to the specific domains rather than to generic study technique. Adjust the pacing to your own residency calendar and consult the full study guide for broader planning.
Chemistry, mechanism and kinetics (Domains 1-4)
- Do this first because every later domain assumes it
- Work calculation problems by hand until clearance, volume and half-life relationships are automatic
Modifiers, routes, forms, harm and failure (Domains 5-9)
- Build cause-and-effect chains linking patient factors to altered exposure or response
- Practice the therapeutic-failure checklist on mock scenarios
System and class pharmacology (Domains 10-22)
- Spend extra time on under-reviewed areas: fluid therapy, botanicals and disinfectants
- Revisit anti-infectives and anticancer drugs for PK/PD integration
Phase II applied reasoning (Domains 23-26)
- Write out full therapeutic and TDM answers, not just selections
- Rehearse study-design critique and regulatory scenarios
Key Takeaway
Keep a one-page "fact sheet" per domain and rebuild it from memory each cycle. Our DACVCP cheat sheet shows the level of compression to aim for, and timed practice at our practice test site helps you rehearse sustained concentration across long sessions.
Where Diplomates Work
Clinical pharmacology residents train in academic veterinary settings, and Diplomates typically work where drug evaluation, therapeutic guidance and research intersect. Common settings include veterinary college faculty and teaching hospitals, pharmaceutical and animal health industry roles involving development and regulatory work, contract research organizations, and government or regulatory-adjacent positions. The Phase II emphasis on regulatory pharmacology, trial design and analytical methods reflects that mix. We have not verified specific compensation figures, so see the qualitative discussion in the DACVCP salary guide, the career overview in DACVCP jobs, and the ROI analysis for how to weigh the investment.
If you are still orienting yourself to the credential, start with what DACVCP stands for, and when you are ready to test your recall across these domains, try the questions at the practice test hub.
Frequently Asked Questions
No. The 26 is a count of the headings supplied here: 22 preparation headings from the December 2021 Phase I blueprint plus the four current Phase II subject categories. It is not an official combined exam-domain count.
They are dated preparation-curriculum topics. The complete current Phase I and Phase II blueprints could not be retrieved during verification, so treat the headings as a study map and confirm the current documents with the ACVCP.
Not in the sources used here. The current Phase II page does not publish category percentages, and historical allocations from the 2021 blueprint should not be treated as current weights.
Phase I is 200 multiple-choice questions in two 100-question sessions. Phase II has ten question groups worth 200 points, using written responses, multiple choice, fill-in-the-blank and extended matching.
Both must be passed within a five-year eligibility period beginning with the first eligible examination year after Phase I approval. This is an examination window, not a renewal interval.